Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies

Next Previous
Trial Profile

A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotamig (Primary) ; Atezolizumab
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Intestinal cancer; Liver cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Arbele

Most Recent Events

  • 26 Apr 2024 According to an Arbele media release, the company announced the positive recommendation from the second meeting of the Data Monitoring Committee (DMC) to continue the A001 Phase I clinical trial evaluating cabotamig (ARB202) in patients with advanced gastrointestinal (GI) cancers without modification to the trial protocol.
  • 02 Aug 2023 According to an Arbele media release, As of 29 Jun 2023, the safety review committee and an independent data monitoring committee, DMC, had approved the trial to continue without modification. The company has completed dosing across the first 3 dose-level cohorts ranging from 0.0003 to 0.003 mg/kg by single IV doses.
  • 02 Aug 2023 Results presented in an Arbele Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top